Cargando...

Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial

SUMMARY: BACKGROUND: In the Denosumab and Teriparatide Administration (DATA) study, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger increases in hip and spine bone mineral density (BMD)...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lancet Diabetes Endocrinol
Main Authors: Tsai, Joy N, Lee, Hang, David, Natalie L, Eastell, Richard, Leder, Benjamin Z
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6980341/
https://ncbi.nlm.nih.gov/pubmed/31447409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(19)30255-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!